Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the
 Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking
 patients with type 1 diabetes. Patients will be treated for 24 months with a 2-month
 follow-up period.
Inclusion Criteria:

 -  Type 1 diabetes

 -  Non smoker

 -  Normal lung function

 Exclusion Criteria:

 -  Significant pulmonary, hepatic, or renal disease

 -  Severe congestive heart failure

 -  Active malignancy

 -  Systemic glucocorticoid therapy